Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks von Kanthaje, Shruthi, Makol, Ankita, Chakraborti, Anuradha

Volltext

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line von Makol, Ankita, Kaur, Harpreet, Sharma, Sakshi, Kanthaje, Shruthi, Kaur, Ramanpreet, Chakraborti, Anuradha

Volltext

Anti-endothelial cell antibody rich sera from rheumatic heart disease patients induces proinflammatory phenotype and methylation alteration in endothelial cells von Rastogi, Mukul, Sarkar, Subendu, Makol, Ankita, Sandip Singh, Rana, Saikia, Uma Nahar, Banerjee, Dibyajyoti, Chopra, Seema, Chakraborti, Anuradha

Volltext

Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma von Makol, Ankita, Kanthaje, Shruthi, Dhiman, Radha K, Kalra, Naveen, Chawla, Yogesh K, Chakraborti, Anuradha

Volltext

15. Sorafenib resistance and metastasis in hepatocellular carcinoma: emerging role of micrornas von Kanthaje, Shruthi, Makol, Ankita, Dhiman, Radha Krishan, Chawla, Yogesh, Kalra, Naveen, Banerjee, Dibyajyoti, Chakraborti, Anuradha

Volltext

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line von Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Volltext